Guanfacine (Intuniv): Uses, Dosing, Side Effects, and Safe Tapering

What It's Used For

Guanfacine is best known in psychiatry as a non-stimulant option for ADHD—especially when the nervous system feels stuck in “on” mode: hyperactivity, impulsivity, emotional snap-reactivity, and sleep/wind-down problems. It’s also commonly considered when tics/Tourette’s are part of the picture, or when stimulant diversion/misuse is a concern.

Primary Indications

ADHD: Helps with hyperactivity, impulsivity, frustration tolerance, and emotional reactivity (often as a calmer, steadier baseline)Tic disorders: Sometimes reduces tic severity, especially when ADHD is also presentTourette syndrome: Often considered when tics + ADHD overlapASD with ADHD symptoms: Used in some kids/teens for hyperactivity/impulsivity, with careful monitoring for irritability

Off-Label Uses

Sleep/wind-down support in ADHD (bedtime sedation can be helpful for some)Adjunct to stimulant medication for partial response or rebound symptomsEmotional dysregulation/irritability in select patients (benefit varies; can also worsen irritability)

How Fast It Works

This is not a “take it and feel it in 30 minutes” medication for ADHD symptoms. The behavioral benefits build over time, while side effects (especially sleepiness and dizziness) can show up early.

First few days to 2 weeks

Sedation/drowsiness and dizziness are most likely to show up (especially after starting or increasing the dose)

Weeks 2 to 6

ADHD symptom benefits often become more obvious as dosing is titrated and the body adapts

Immediate-release peak

~1 to 4 hours after a dose (Tmax ~2.6 hours)

Extended-release peak

~4 to 8 hours after a dose (designed for once-daily coverage)

Half-life

~17 to 18 hours on average (effects can carry into the next day for some people)

Safe Discontinuation

Guanfacine should be tapered—not stopped abruptly—because sudden discontinuation can trigger a withdrawal syndrome and rebound hypertension. Withdrawal symptoms can look like a catecholamine “surge”: nervousness/anxiety feelings, agitation, headache, tremor, and a rise in blood pressure (sometimes above baseline).

Key Points

Main risk: rebound hypertension and withdrawal symptoms if stopped suddenly
Higher risk with: higher doses, longer duration, and abrupt interruption (including missed doses, vomiting, or inability to absorb oral meds)
Extended-release taper: decrease by no more than 1 mg every 3 to 7 days
Immediate-release taper: reduce gradually (often stepwise over days to weeks depending on dose and duration), watching blood pressure/heart rate and withdrawal symptoms
Missed doses: if ≥2 consecutive doses are missed (extended-release), consider restarting at a lower dose and retitrating rather than jumping back in
Perioperative note: guanfacine therapy generally should not be interrupted during the perioperative period; coordinate plans in advance

Dosing Information

Adult Dosing

not applicable: Intuniv (extended-release guanfacine) is FDA-approved for ADHD in ages 6 to 17. Adult psychiatric dosing is not set in FDA labeling; if used off-label in adults, dosing should be guided by a specialist, with slow titration and close blood pressure and heart-rate monitoring.

Simple Explanation

Immediate-release (IR) and extended-release (ER) guanfacine are not interchangeable dose-for-dose. ER is designed for once-daily coverage with a lower peak and different exposure profile. ER tablets must be swallowed whole and should not be taken with a high-fat meal.

Available Formulations

Tablet, oral (immediate-release): 1 mg, 2 mg (generics available; historically branded as Tenex in the U.S.)
Tablet, oral, extended-release 24 hour (Intuniv / Intuniv XR and generics): 1 mg, 2 mg, 3 mg, 4 mg

Critical Safety Information

Do not stop guanfacine abruptly. Withdrawal can cause rebound hypertension and a jittery, revved-up withdrawal syndrome.

→If you miss doses or want to stop, don’t wing it—taper slowly to reduce rebound blood pressure spikes and withdrawal symptoms (nervousness, agitation, headache, tremor).
→Stand up slowly, especially early on. Hydrate. Dehydration makes dizziness and fainting more likely.
→Avoid alcohol and other sedating meds unless your clinician specifically signs off—sedation stacks.
→Tell your clinician if you have a history of fainting, slow heart rate, low blood pressure, heart block, or major heart disease.
→If you get chest pain, fainting, severe dizziness, or unusually slow heart rate, get evaluated urgently.
→Do not swap IR and ER products dose-for-dose. They behave differently in the body.

Side Effects

Most common: sleepiness, fatigue, dizziness, headache, and dry mouth. The big watch-outs are low blood pressure, slow heart rate, and fainting—especially early in treatment, after dose increases, and with dehydration or other blood pressure meds.

Common Things People Notice

Sleepiness / drowsiness (very common, dose-related)
Fatigue / low energy
Dizziness or lightheadedness (especially standing up)
Headache
Dry mouth
Constipation or stomach upset
Insomnia or weird sleep (yes, paradoxically, both can happen)

Common Side Effects

Immediate-release: 5% to 39%; Extended-release (pediatric trials): 28% to 57%

Drowsiness / Sedation— Sedation often hits early (first few weeks) and after dose increases. For some people it fades; for others it’s the limiting factor. Timing the dose (morning vs evening) is often adjusted around this.

Immediate-release: 12% to 15%; Extended-release (pediatric trials): 4% to 16%

Dizziness / Lightheadedness— This is often a low blood pressure/orthostatic issue. Dehydration and rapid position changes make it worse.

Immediate-release: 5% to 10%; Extended-release (pediatric trials): 10% to 22%

Fatigue— Fatigue can look like low motivation, slowed drive, or needing naps—especially early on.

Immediate-release: 3% to 13%; Extended-release (pediatric trials): 16% to 28%

Headache— Headache can occur early in treatment and during dose changes. Hydration and slow titration matter.

Immediate-release: 10% to 54%; Extended-release (pediatric trials): 3% to 8%

Dry Mouth (Xerostomia)— Classic central alpha-agonist side effect. Water, sugar-free gum, and oral care help.

Extended-release (pediatric trials): abdominal pain 8% to 19%; constipation 2% to 4%; nausea 5% to 7%; vomiting 2% to 7%

GI Effects (abdominal pain, constipation, nausea)— Often dose-related and sometimes improves over time.

Extended-release (pediatric trials): irritability 5% to 8%; emotional lability 2% to 3%; agitation ≥2%

Irritability / Emotional Lability— Some patients—especially those with ASD—seem more sensitive to irritability-type effects. Slower titration can help clarify if this is a temporary adjustment effect or a deal-breaker.

Serious side effects

Syncope (fainting), marked hypotension, or clinically significant bradycardia: higher risk with dehydration, heart disease, conduction abnormalities, or other sympatholytic/blood pressure meds
Atrioventricular (AV) block or rhythm disturbances (rare): evaluate if palpitations, fainting, or severe dizziness occur
Withdrawal syndrome with abrupt discontinuation: nervousness/agitation symptoms and rebound hypertension; in severe cases, hypertensive complications have been reported
Seizure (rare; reported postmarketing): evaluate urgently if seizure occurs
Hallucinations or confusion (rare; postmarketing): consider medication contribution and evaluate medically

Critical Drug Interactions

Guanfacine is a CYP3A4 substrate and also has additive effects with other meds that lower blood pressure/heart rate or cause sedation. The biggest practical problems are: getting too sleepy, getting too dizzy, or having your heart rate/blood pressure drop too far.

With: Alcohol

Risk: Additive sedation and dizziness; worsens impaired alertness and increases fall/fainting risk.

Action: Avoid or minimize. If alcohol is used, it should be discussed explicitly because sedation can stack fast.

With: Other sedating medications (benzodiazepines, barbiturates, sedating antihistamines, antipsychotics, sleep meds)

Risk: Additive CNS depression: more sedation, slower reaction time, impaired driving/school/work performance.

Action: Use caution. Consider dose timing, slower titration, or non-sedating alternatives when possible.

With: Antihypertensives and sympatholytic agents (beta blockers, alpha blockers, mixed alpha/beta blockers)

Risk: More hypotension, bradycardia, orthostasis, and fainting risk.

Action: Monitor blood pressure and heart rate closely, especially during initiation and dose changes.

With: CYP3A4 inhibitors (examples: ketoconazole, clarithromycin, some HIV protease inhibitors)

Risk: Higher guanfacine levels → more sedation, hypotension, bradycardia.

Action: Dose/frequency adjustment or avoidance may be needed; monitor for excess effects.

With: CYP3A4 inducers (examples: carbamazepine, phenytoin, rifampin, St. John’s wort)

Risk: Lower guanfacine levels → reduced benefit and potential rebound symptoms if levels drop quickly.

Action: Avoid when possible; if used, clinical response may change and dose adjustments may be needed.

With: Grapefruit juice/products

Risk: May increase guanfacine concentrations (more sedation and cardiovascular effects).

Action: Avoid grapefruit products, or consider dose reduction (commonly by ~50% when grapefruit is consistently used) with monitoring.

With: Stimulants (adjunct use)

Risk: Often a helpful combination, but blood pressure/heart rate effects can be less predictable and sedation can still be limiting.

Action: Monitor vitals at baseline, after dose changes, and periodically; adjust timing/dosing based on alertness and vitals.

Pregnancy, Breastfeeding, Special Groups

Guanfacine can be clinically useful in child and adolescent psychiatry, but it requires extra caution in anyone at risk for low blood pressure, slow heart rate, fainting, or sedation. Pregnancy and lactation data are limited, so risk/benefit discussions matter a lot.

👶Pregnancy

Guanfacine is not considered a preferred medication for chronic hypertension in pregnancy, and outcome data for guanfacine exposure in pregnancy are limited. For ADHD, many experts recommend discontinuing guanfacine during pregnancy when possible due to limited data and the availability of non-medication supports. If exposure occurs, discuss risks and monitoring, and consider enrolling in the National Pregnancy Registry for ADHD Medications.

🤱Breastfeeding

It is not known whether guanfacine is present in breast milk. If used during breastfeeding, monitor the infant for lethargy, poor feeding, and sedation. Decisions should weigh infant exposure risk, breastfeeding benefits, and maternal treatment benefits.

👧Children & Adolescents (Under 18)

ADHD (extended-release, ages 6 to 17): Start 1 mg once daily at the same time each day (morning or evening). Titrate by no more than 1 mg per week based on response and tolerability. Target range commonly referenced: 0.05 to 0.12 mg/kg/day (or roughly 1 to 7 mg/day within age-based maximums). Maximums not evaluated above: monotherapy—children 6 to 12 years: 4 mg/day; adolescents 13 to 17 years: 7 mg/day. Adjunct to stimulants: doses above 4 mg/day have not been evaluated. If converting from IR to ER: discontinue IR and start ER using ER titration (do not convert mg-for-mg). Missed ER doses: if ≥2 consecutive doses missed, consider repeating titration. Discontinuation ER: taper by ≤1 mg every 3 to 7 days. ASD + ADHD (comorbidity, limited data, often IR in reports): dosing is individualized with slow increments and close monitoring for irritability. Tourette/tics (limited data, often IR): titration schedules exist in studies, commonly starting low at bedtime and increasing in small steps every few days toward a divided-dose total, with careful monitoring of sedation and vitals.

👴Older Adults (65+)

Avoid as a routine antihypertensive in adults ≥65 per Beers Criteria due to CNS adverse effects and risk of bradycardia/orthostatic hypotension. For psychiatric use in older adults, if considered at all, start very low, titrate slowly, and monitor vitals and falls risk closely.

🔬Liver Impairment

No specific adult dose adjustment is provided in labeling, but use caution in chronic hepatic impairment. For ER in pediatrics, it has not been studied in significant hepatic impairment; dose adjustments may be necessary. Consider slower titration and lower target doses if side effects emerge.

💧Kidney Impairment

Adult labeling does not provide a specific adjustment, and dose adjustment is often unlikely based on pharmacokinetic evidence; however, use caution in chronic renal impairment. Pediatric IR guidance commonly recommends using the lower end of dosing in renal impairment. Hemodialysis clearance is low (~15% of total clearance).

Clinical Monitoring

Blood pressure and heart rate: check before starting, after dose increases, and periodically thereafter; watch for hypotension, bradycardia, and orthostatic symptoms
Syncope risk: ask about fainting, near-fainting, dizziness on standing; assess hydration and other BP-lowering meds
Sedation/alertness: monitor daytime sleepiness, school/work functioning, driving safety, and morning “hangover” effects
Mood/behavior: track irritability, agitation, emotional lability, anxiety-like activation with missed doses, and any worsening mood symptoms
ADHD cardiovascular screening (pediatrics): thorough patient/family history and physical exam focused on cardiovascular risk; ECG is not mandatory but can be reasonable to consider, especially if risk factors or symptoms exist
Medication adherence: missed doses matter with guanfacine (withdrawal/rebound risk). Create a plan for missed doses and retitration when needed
Drug interactions: review CYP3A4 inhibitors/inducers, grapefruit intake, and all sedating meds at every visit
Growth/weight (pediatrics): appetite changes and weight gain are possible; monitor trends over time

How Well It Works

ADHD symptom improvement (hyperactivity/impulsivity, emotional reactivity)

Varies by person and dose tolerance

Guanfacine extended-release can meaningfully improve ADHD symptoms—especially hyperactivity, impulsivity, and emotional snap-reactivity—without being a stimulant. The usable dose is often limited by sleepiness and effects on the heart and blood pressure (low blood pressure and slow heart rate), so the “best” dose is the one that helps symptoms without making you too drowsy to function.

Mechanism of Action

Guanfacine is a selective alpha-2A adrenergic receptor agonist. In the body, it reduces sympathetic outflow—lowering heart rate and blood pressure. In the brain (especially the prefrontal cortex), alpha-2A signaling is tied to attention regulation, working memory, and behavioral inhibition. The practical effect: fewer impulsive “snap” reactions, less motor restlessness, and a steadier ability to pause and choose.

Place in Treatment Algorithm

In ADHD treatment, guanfacine ER sits in the non-stimulant lane. It’s often used when stimulants aren’t tolerated, don’t work after an adequate trial, or aren’t a good idea due to diversion/misuse concerns. Clinically, it’s also a frequent choice when tics/Tourette’s are comorbid, because it can support ADHD symptoms without the same tic-worsening worries some patients have with stimulants. It can be used as monotherapy or added to a stimulant when the stimulant helps but doesn’t fully cover impulsivity, emotional reactivity, or late-day rebound. The main limiter is side effects: sedation, dizziness, hypotension, and bradycardia—so titration speed and dose timing are everything.

Questions people ask

What is Intuniv used for in psychiatry?

Intuniv (guanfacine extended-release) is used to treat ADHD—especially symptoms like hyperactivity, impulsivity, and emotional overreacting. It’s often considered when stimulants cause side effects, don’t work well enough, or aren’t a good idea due to diversion/misuse risk. It can be used alone or alongside a stimulant.

Is guanfacine a stimulant?

No. Guanfacine is not a stimulant. It’s an alpha-2A adrenergic agonist that tends to calm and steady the nervous system rather than “rev it up.”

How long does guanfacine take to work for ADHD?

The ADHD benefits usually build over days to weeks, especially as the dose is slowly raised. Side effects like sleepiness and dizziness often show up earlier—sometimes within the first few days and after dose increases.

Why does guanfacine make people sleepy?

Because it reduces norepinephrine signaling in a way that can lower arousal. That can be helpful for wind-down and impulsive overactivation, but it can also cause daytime drowsiness—especially early in treatment or at higher doses.

Can guanfacine help with sleep or bedtime shutdown?

For some people with ADHD, yes—mainly because sedation can be a side effect. If sleepiness is the main benefit, dose timing (evening dosing) sometimes helps. The goal is controlled calm, not being knocked out.

Can Intuniv be taken with stimulant medication?

Yes. Guanfacine ER can be added to a stimulant. This combination is often used when stimulants help attention but impulsivity, emotional reactivity, or rebound symptoms still break through. Blood pressure, heart rate, and sleepiness should be monitored.

Does guanfacine help with tics or Tourette’s?

It can for some people, especially when ADHD is also present. Results are mixed across studies, so it’s not a guaranteed tic medication—but it’s commonly considered in the tics + ADHD overlap zone.

What happens if I stop guanfacine suddenly?

Don’t do it. Abrupt discontinuation can trigger withdrawal symptoms and rebound hypertension (a blood pressure spike). People may feel jittery, anxious, agitated, get headaches or tremors, and have a noticeable rise in blood pressure. Tapering is the safer move.

What if I miss doses?

Missed doses matter because of withdrawal and rebound risk. If you miss two or more doses of extended-release guanfacine in a row, clinicians often consider restarting at a lower dose and stepping back up rather than jumping right back to the previous dose.

Can I drink alcohol while taking guanfacine?

It’s a bad idea. Alcohol can stack sedation and dizziness and increase the risk of fainting or falls. If alcohol is part of your life, talk about it directly so dosing and timing can be safer.

Why do clinicians watch blood pressure and heart rate with guanfacine?

Because guanfacine calms the body’s “fight or flight” nervous system. That can lower blood pressure and slow heart rate, sometimes enough to cause dizziness, lightheadedness when standing up, or fainting—especially early on, after dose increases, or with dehydration.

Are IR guanfacine and Intuniv XR interchangeable?

No. Immediate-release and extended-release guanfacine are not interchangeable mg-for-mg. The body absorbs and handles them differently, so the amount that reaches your blood is not the same. Switching between them should be done deliberately with a clinician’s plan.

Do grapefruit products matter with guanfacine?

Yes. Grapefruit can increase guanfacine levels, which can mean more sedation and more blood pressure/heart rate effects. Many clinicians recommend avoiding grapefruit products while taking guanfacine.